Goyal RK - Search Results

1

Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer.

Brufsky A, Kwan ML, Sandin R, Stergiopoulos S, Karanth S, Cha-Silva AS, Makari D, Goyal RK. Brufsky A, et al. Among authors: goyal rk. Breast Cancer Res Treat. 2024 Nov;208(2):223-235. doi: 10.1007/s10549-024-07469-6. Epub 2024 Aug 23. Breast Cancer Res Treat. 2024. PMID: 39177933 Free PMC article. Review.

2

Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States.

Goyal RK, Holmes HM, Chen H, Abughosh S, Candrilli SD, Johnson ML. Goyal RK, et al. Breast Cancer Res Treat. 2023 Feb;198(1):159-166. doi: 10.1007/s10549-022-06845-4. Epub 2023 Jan 7. Breast Cancer Res Treat. 2023. PMID: 36609900

3

Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer.

Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Goyal RK, et al. Breast Cancer Res Treat. 2024 May;205(1):201-210. doi: 10.1007/s10549-023-07080-1. Epub 2024 Feb 4. Breast Cancer Res Treat. 2024. PMID: 38310616 Free PMC article.

4

Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study.

Goyal RK, Chen H, Abughosh SM, Holmes HM, Candrilli SD, Johnson ML. Goyal RK, et al. Cancer. 2023 Apr 1;129(7):1051-1063. doi: 10.1002/cncr.34675. Epub 2023 Feb 9. Cancer. 2023. PMID: 36760031 Free article.

5

Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.

Furqan M, Karanth S, Goyal RK, Cai B, Rombi J, Davis KL, Caro N, Saliba T. Furqan M, et al. Among authors: goyal rk. Future Oncol. 2024;20(22):1553-1563. doi: 10.2217/fon-2023-1064. Epub 2024 Apr 17. Future Oncol. 2024. PMID: 38629593 Free PMC article.

6

Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug Conjugate Therapy.

Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Goyal RK, et al. Breast Cancer (Dove Med Press). 2023 Nov 17;15:855-865. doi: 10.2147/BCTT.S422025. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 38020049 Free PMC article.

7

Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer.

Goyal RK, Candrilli SD, Abughosh S, Chen H, Holmes HM, Johnson ML. Goyal RK, et al. Cancers (Basel). 2024 Jun 7;16(12):2168. doi: 10.3390/cancers16122168. Cancers (Basel). 2024. PMID: 38927874 Free PMC article.

8

Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer.

Goyal RK, Carter GC, Nagar SP, Smyth EN, Price GL, Huang YJ, Li L, Davis KL, Kaye JA. Goyal RK, et al. Curr Med Res Opin. 2019 Oct;35(10):1699-1710. doi: 10.1080/03007995.2019.1615422. Epub 2019 Jun 12. Curr Med Res Opin. 2019. PMID: 31060392

9

Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.

Goyal RK, Nagar SP, Kabadi SM, Le H, Davis KL, Kaye JA. Goyal RK, et al. Cancer Med. 2021 Apr;10(8):2690-2702. doi: 10.1002/cam4.3855. Epub 2021 Mar 18. Cancer Med. 2021. PMID: 33734606 Free PMC article.

10

Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States.

Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Goyal RK, et al. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):699-710. doi: 10.1080/14737167.2020.1804871. Epub 2020 Sep 14. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 32755262

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

598 results

Search Page

Filters